Sutro Biopharma snags $85.4 mln Series E

South San Francisco-based Sutro Biopharma Inc, a drug developer, has secured $85.4 million in Series E financing. Samsara BioCapital and Surveyor Capital led the round with participation from other investors that included Alta Partners, Amgen Ventures, Celgene Corporation, Lilly Ventures, Skyline Ventures and SV Health Investors. In addition to the funding, Dr. Mike Dybbs, a partner at Samsara BioCapital, will join the Sutro board of directors.

Source: Press Release

PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.

Find new deal opportunities, super-charge your fundraising efforts and track top managers with VCJ. Get your FREE trial! Or subscribe now!